BACKGROUND: Data are scarce about whether past history of major depressive disorder in the absence of current depression places breast cancer patients at risk for worse quality of life. PURPOSE: The current study prospectively examined quality of life during chemotherapy in breast cancer patients with a history of resolved major depressive disorder (n = 29) and no history of depression (n = 144). METHODS: Women with Stages 0-II breast cancer were assessed prior to and at the completion of chemotherapy. Major depressive disorder was assessed via structured interview and quality of life with the SF-36. RESULTS: Patients with past major depressive disorder displayed greater declines in physical functioning relative to patients with no history of depression (p ≤ 0.01). CONCLUSIONS: Findings suggest that breast cancer patients with a history of resolved major depressive disorder are at increased risk for declines in physical functioning during chemotherapy relative to patients with no history of depression.
BACKGROUND: Data are scarce about whether past history of major depressive disorder in the absence of current depression places breast cancerpatients at risk for worse quality of life. PURPOSE: The current study prospectively examined quality of life during chemotherapy in breast cancerpatients with a history of resolved major depressive disorder (n = 29) and no history of depression (n = 144). METHODS:Women with Stages 0-II breast cancer were assessed prior to and at the completion of chemotherapy. Major depressive disorder was assessed via structured interview and quality of life with the SF-36. RESULTS:Patients with past major depressive disorder displayed greater declines in physical functioning relative to patients with no history of depression (p ≤ 0.01). CONCLUSIONS: Findings suggest that breast cancerpatients with a history of resolved major depressive disorder are at increased risk for declines in physical functioning during chemotherapy relative to patients with no history of depression.
Authors: Hyong Jin Cho; Helen Lavretsky; Richard Olmstead; Myron Levin; Michael N Oxman; Michael R Irwin Journal: Am J Geriatr Psychiatry Date: 2010-05 Impact factor: 4.105
Authors: D A Solomon; M B Keller; A C Leon; T I Mueller; P W Lavori; M T Shea; W Coryell; M Warshaw; C Turvey; J D Maser; J Endicott Journal: Am J Psychiatry Date: 2000-02 Impact factor: 18.112
Authors: Kelly-Anne Phillips; Richard H Osborne; Graham G Giles; Gillian S Dite; Carmel Apicella; John L Hopper; Roger L Milne Journal: J Clin Oncol Date: 2008-10-01 Impact factor: 44.544
Authors: Hyong Jin Cho; Helen Lavretsky; Richard Olmstead; Myron J Levin; Michael N Oxman; Michael R Irwin Journal: Am J Psychiatry Date: 2008-09-02 Impact factor: 18.112
Authors: Paul B Jacobsen; Kristine A Donovan; Brent J Small; Heather S Jim; Pamela N Munster; Michael A Andrykowski Journal: Cancer Date: 2007-10-15 Impact factor: 6.860
Authors: E S Costanzo; S K Lutgendorf; M L Mattes; S Trehan; C B Robinson; F Tewfik; S L Roman Journal: Br J Cancer Date: 2007-11-13 Impact factor: 7.640
Authors: Barbara L Andersen; Neha Godiwala Goyal; Travis D Westbrook; Brenden Bishop; William E Carson Journal: Clin Cancer Res Date: 2016-07-12 Impact factor: 12.531
Authors: Bonnie A McGregor; Emily D Dolan; Karly M Murphy; Timothy S Sannes; Krista B Highland; Denise L Albano; Alison A Ward; Anna M Charbonneau; Mary W Redman; Rachel M Ceballos Journal: Ann Behav Med Date: 2015-12
Authors: Erin L O'Hea; Brigitte R Monahan; Alexandra Cutillo; Sharina D Person; Grant Grissom; Edwin D Boudreaux Journal: J Health Psychol Date: 2014-09-09
Authors: Lara C Weinstein; Ana Stefancic; Amy T Cunningham; Katelyn E Hurley; Leopodo J Cabassa; Richard C Wender Journal: CA Cancer J Clin Date: 2015-12-10 Impact factor: 508.702
Authors: Nancy K Janz; Christopher R Friese; Yun Li; John J Graff; Ann S Hamilton; Sarah T Hawley Journal: J Cancer Surviv Date: 2013-11-13 Impact factor: 4.442